Amphastar Licenses Exclusive Rights to Synthetic Corticotropin (AMP-110) for US/Canada Market

summarizeSummary

Amphastar Pharmaceuticals secured an exclusive license for AMP-110, a synthetic corticotropin compound, for the US and Canadian markets, expanding its proprietary peptide pipeline into inflammatory and autoimmune conditions.

check_boxKey Events

• Exclusive License Agreement

  Amphastar entered an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for AMP-110, a synthetic corticotropin compound, in the United States and Canada.

• Significant Potential Payments

  The agreement includes an upfront payment of $2 million, up to $14 million in development milestones, and up to $75 million in sales milestones, plus royalties capped at $60 million.

• Pipeline Expansion

  AMP-110, currently in early-phase clinical development, is designed for inflammatory and autoimmune conditions, expanding Amphastar's proprietary peptide portfolio into a market exceeding $684 million annually.

• Related Party Transaction

  The agreement is a related-party transaction, as Amphastar's CEO and COO and their family beneficially own a majority of Hanxin; the Audit Committee approved the transaction.

auto_awesomeAnalysis

This agreement marks a strategic expansion for Amphastar into the substantial adrenocorticotropic hormone (ACTH) market with a new, fully synthetic compound, AMP-110. While the upfront payment is modest, the potential for up to $151 million in milestone and royalty payments represents a significant long-term commitment tied to the product's development and commercial success. The related-party nature of the transaction, involving the CEO and COO's family, was disclosed and approved by the Audit Committee, which is a positive for governance. Investors should monitor AMP-110's clinical development progress and future milestone achievements as this product could become a meaningful contributor to Amphastar's proprietary portfolio.